Novartis gene therapy for fatal childhood disease delivers strong sales during fourth quarter

Zolgensma, the Novartis gene therapy for infants and the world’s most expensive medicine, continues to perform well commercially, bringing in $186 million during the fourth quarter, topping analyst expectations on Wednesday.